2. Protein Tyrosine Kinase/RTK Cell Cycle/DNA Damage
  3. VEGFR CDK
  4. VEGFR2-IN-86

VEGFR2-IN-86 是一种双重 VEGFR2/CDK2 抑制剂，对 VEGFR2 的 IC50 为 0.06 μM，对 CDK2 的 IC50 为 0.78 μM。VEGFR2-IN-86 可诱导 G 期细胞周期阻滞，降低集落形成能力与肿瘤细胞迁移能力，在癌细胞中发挥抗增殖活性。VEGFR2-IN-86 可用于乳腺癌、前列腺癌的研究。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

VEGFR2-IN-86

VEGFR2-IN-86 Chemical Structure

1.  客户无需承担相应的运输费用。

2.  同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户。

规格 是否有货
50 mg   询价  
100 mg   询价  
250 mg   询价  

* Please select Quantity before adding items.

Customer Review

VEGFR2-IN-86 相关抗体

Top Publications Citing Use of Products

查看 VEGFR 亚型特异性产品:

查看所有亚型
VEGFR1/Flt-1 VEGFR2/KDR/Flk-1 VEGFR3/Flt-4

查看 CDK 亚型特异性产品:

查看所有亚型
CDK1 CDK2 CDK3 CDK4 CDK5 CDK6 CDK7 CDK8 CDK9 CDK11 CDK12 CDK13 CDK14 CDK16 CDK19 CDC CLK Pho85 CDK10 CDK15 CDK17 CDK18 CDK20 PITSLRE

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

VEGFR2-IN-86 is a dual VEGFR2/CDK2 inhibitor, with an IC50 of 0.06 μM against VEGFR2 and an IC50 of 0.78 μM against CDK2. VEGFR2-IN-86 induces G-phase cell cycle arrest, reduces colony-forming ability and tumor cell migration capacity, and exerts antiproliferative activity in cancer cells. VEGFR2-IN-86 can be used for the research of breast cancer and prostate cancer[1].

IC50 & Target[1]

VEGFR2

0.06 μM (IC50)

CDK2

0.78 μM (IC50)

体外研究
(In Vitro)

VEGFR2-IN-86 (Compound 10) (48 h) 可强效抑制 PC3 和 MCF7 细胞的活力， IC50 为 5.39 和 4.71 μM[1]。
VEGFR2-IN-86 (5.39 和 4.71 μM; 48 h) 在以其 IC50 浓度作用 48 小时后，可诱导 PC3 和 MCF7 细胞发生凋亡[1]。
VEGFR2-IN-86 (5.39 和 4.71 μM; 48 h) 不会显著改变 PC3 和 MCF7 细胞的细胞周期时相分布[1]。
VEGFR2-IN-86 (5.39 和 4.71 μM; 48 h) 当其以 IC50 浓度作用 48 小时时，可强效抑制 PC3 和 MCF7 细胞的长期克隆形成存活能力[1]。
VEGFR2-IN-86 (5.39 和 4.71 μM; 48 h) 抑制PC3 和 MCF7 细胞迁移[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

VEGFR2-IN-86 相关抗体:

Cell Cycle Analysis[1]

Cell Line: PC3 prostate cancer cell line
Concentration: 5.39 μM (IC50)
Incubation Time: 48 h
Result: Resulted in a cell cycle phase distribution pattern comparable to untreated control cells, with no significant alteration in G1, S, or G2/M phase populations relative to control.

Cell Cycle Analysis[1]

Cell Line: MCF7 breast cancer cell line
Concentration: 4.71 μM (IC50)
Incubation Time: 48 h
Result: Produced no significant alterations in G1, S, or G2/M phase populations relative to untreated control cells.

Cell Proliferation Assay[1]

Cell Line: PC3 prostate cancer cell line
Concentration: 5.39 μM (IC50)
Incubation Time: 48 h (treatment); 14 days (colony formation)
Result: Markedly suppressed colony formation, resulting in a surviving fraction significantly lower than that of untreated control cells.

Cell Proliferation Assay[1]

Cell Line: MCF7 breast cancer cell line
Concentration: 4.71 μM (IC50)
Incubation Time: 48 h (treatment); 14 days (colony formation)
Result: Markedly suppressed colony formation, resulting in a surviving fraction significantly lower than that of untreated control cells.

Cell Migration Assay[1]

Cell Line: PC3 prostate cancer cell line
Concentration: 5.39 μM (IC50)
Incubation Time: 48 h
Result: Resulted in a scratch closure percentage of 73%, showing a slight reduction compared to the untreated control's 78% closure.

Cell Migration Assay[1]

Cell Line: MCF7 breast cancer cell line
Concentration: 4.71 μM (IC50)
Incubation Time: 48 h
Result: Resulted in a scratch closure percentage of 26%, showing a marked reduction compared to the untreated control's 64% closure.
分子量

329.35

Formula

C20H15N3O2
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
参考文献

VEGFR2-IN-86 相关分类

  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

VEGFR2-IN-86VEGFRCDKVascular endothelial growth factor receptorCyclin dependent kinaseMCF7VEGFR2PC3prostate cancerCDK2HaCaTbreast cancercell cycle progressionMCF10Atumor angiogenesisInhibitorinhibitorinhibit

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称：

  

* 需求量：

* 客户姓名：

 

* Email：

* 电话：

 

* 公司或机构名称：

   留言给我们：

Bulk Inquiry

Inquiry Information

产品名称：
VEGFR2-IN-86
目录号：
HY-182789
需求量：

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

   产品名称：

  

* Lot #：

* 客户姓名：

 

* Email：

   电话：

 

* 部门：

* 公司或机构名称：

 

   留言给我们：

Request for HNMR Report

We have received your request and will respond to you as soon as possible.

嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z